Vertex Announces Fda Clearance Of Investigational New Drug Application For Vx-264
Vertex Pharmaceuticals Incorporated Announced That The U.S. Food And Drug Administration (Fda) Has Cleared The Investigational New Drug Application (Ind) For Vx-264, A Stem Cell-Derived, Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into A Vertex-Developed, Immunoprotective Device With The Potential To Treat Type 1 Diabetes (T1D). The Vx-264 Programme Does Not Require The Use Of Immunosuppression, Which May Broaden The Population Of People With T1D That This Investigational Therapy Could Reach.Vx-264 Is An Investigational Cell Therapy In Which Allogeneic Human Stem Cell-Derived Islets Are Encapsulated In A Channel Array Device Designed To Shield The Cells From The Body
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!